provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeDrugsBiologics
02:31

Why Do Biologics Typically Cost So Much More Than Traditional Medications?

Biologic medications have complex development, approval, and storage needs.

Lauren Smith, MAAlexandra Schwarz, MD
Written by Lauren Smith, MA | Reviewed by Alexandra Schwarz, MD
Published on November 9, 2023

Biologic medications have offered relief to many people living with difficult-to-treat conditions. The problem is, they tend to cost much more than other types of medications.

In this video, learn what makes biologics unique and complex, and how that affects the price, according to Stacia Woodcock, PharmD, Pharmacy Editor at GoodRx Health, and Alyssa Billingsley, PharmD, Director of Pharmacy Content at GoodRx Health.

Advertisement
Additional Medical Contributors (2)
  • Stacia Woodcock, PharmDStacia Woodcock, PharmD, is a pharmacy editor for GoodRx. She earned her Doctor of Pharmacy degree from the University of Kentucky and is licensed in New York and Massachusetts.
    • Alyssa Billingsley, PharmDAlyssa Billingsley, PharmD, is a pharmacist on the GoodRx team with a decade of experience. She is also an adjunct faculty at St. Louis College of Pharmacy, where she graduated with a doctorate in pharmacy. She is licensed to practice in Missouri and is a member of the National Council of Prescription Drug Programs (NCPDP) and the Healthcare Information and Management Systems Society (HIMSS). Prior to GoodRx, Alyssa worked in both clinical and administrative roles. She was recognized with the Distinguished Alumnus Outstanding Achievement Award in 2017 for her work in developing pharmacy programs to expand patient access to quality medications.

      References

      National Institutes of Health. (n.d.). Biologic.

      Federal Trade Commission. (2023). Are you on a biologic medication? What you need to know about biosimilar treatment options.

      View All References (2)

      U.S. Food and Drug Administration. (2023). Biosimilar basics for patients.

      U.S. Food and Drug Administration. (2023). Purple book database of licensed biological products: Patent list.

      GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

      Was this page helpful?

      Subscribe and save.

      Get prescription saving tips and more from GoodRx Health. Enter your email to sign up.

      By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.